Disease Overview
Dengue fever is an emerging flaviviral infection transmitted mainly by Aedes aegypti and Aedes albopictus mosquitoes. The dengue burden has expanded rapidly over the last few decades, and the disease is now endemic in many Latin American and Asia-Pacific countries, with 75% of the at-risk population residing in the latter region. Dengue usually manifests as a severe flu-like illness, with symptoms including headache, retro-orbital pain, muscle pain, and vomiting, but 1-3% of infections will manifest as dengue hemorrhagic fever, characterized by plasma leakage, severe bleeding, and respiratory distress.
Market Snapshot
Dengue fever is an emerging flaviviral infection transmitted mainly by Aedes aegypti and Aedes albopictus mosquitoes. The dengue burden has expanded rapidly over the last few decades, and the disease is now endemic in many Latin American and Asia-Pacific countries, with 75% of the at-risk population residing in the latter region. Dengue usually manifests as a severe flu-like illness, with symptoms including headache, retro-orbital pain, muscle pain, and vomiting, but 1-3% of infections will manifest as dengue hemorrhagic fever, characterized by plasma leakage, severe bleeding, and respiratory distress.
Market Snapshot
- Safety concerns in seronegative patients will severely lower Dengvaxia’s uptake for the foreseeable future.
- TAK-003 is expected to replace Dengvaxia as the preferred vaccine for routine immunizations in lucrative Asia-Pacific markets.
Table of Contents
MARKETED VACCINES: DENGUE FEVER (Published on 04 January 2018)EXECUTIVE SUMMARY
PRODUCT PROFILE: DENGVAXIA
PIPELINE VACCINES: DENGUE FEVER (Published on 04 January 2018)
EXECUTIVE SUMMARY
CLINICAL PIPELINE OVERVIEW
PRIMARY RESEARCH METHODOLOGY
PRODUCT PROFILE (LATE STAGE): DPIV
PRODUCT PROFILE (LATE STAGE): DENGUE DNA VACCINE
PRODUCT PROFILE (LATE STAGE): TAK-003
PRODUCT PROFILE (LATE STAGE): TETRAVAX-DV
PRODUCT PROFILE (LATE STAGE): V180
List of Figures
Figure 1: Dengvaxia vaccine design
Figure 2: Dengvaxia for dengue fever - SWOT analysis
Figure 3: DPIV for dengue fever - SWOT analysis
Figure 4: Dengue DNA Vaccine for dengue fever - SWOT analysis
Figure 5: Design of the TAK-003 vaccine
Figure 6: TAK-003 for dengue fever - SWOT analysis
Figure 7: Design of the TetraVax-DV vaccine
Figure 8: TetraVax-DV for dengue fever - SWOT analysis
Figure 9: V180 for dengue fever - SWOT analysis
List of Tables
Table 1: Dengvaxia drug profile
Table 2: Dengvaxia pivotal trial data in dengue fever
Table 3: Dengvaxia ongoing late-phase trials in dengue fever
Table 4: Pipeline products in development for dengue fever prophylaxis
Table 5: DPIV drug profile
Table 6: DPIV completed Phase I studies in dengue fever
Table 7: DPIV ongoing studies in dengue fever
Table 8: Dengue DNA Vaccine drug profile
Table 9: Dengue DNA Vaccine Phase I data in dengue fever
Table 10: Dengue DNA Vaccine Phase I data in dengue fever
Table 11: Potential dosing schedules of early-phase dengue fever vaccine candidates
Table 12: TAK-003 drug profile
Table 13: TAK-003 completed studies in dengue fever
Table 14: TAK-003 ongoing studies in dengue fever
Table 15: TAK-003 Phase II trial data in dengue fever
Table 16: TetraVax-DV drug profile
Table 17: TetraVax-DV completed studies in dengue fever
Table 18: TetraVax-DV ongoing studies in dengue fever
Table 19: V180 drug profile
Table 20: V180 Phase I data in dengue fever
